Crizotinib: A targeted therapy in advanced ALK-positive non-small cell lung cancer

被引：0
|
作者：
Toffart, A. -C. [1 ,2 ]
Sakhri, L. [1 ,2 ]
Moro-Sibilot, D. [1 ,2 ]
机构：
[1] Ctr Hosp Univ A Michallon, UM Oncol Thorac, F-38043 Grenoble 9, France
[2] Univ Grenoble 1, Inst A Bonniot, INSERM, U823, Grenoble, France
来源：
REVUE DE PNEUMOLOGIE CLINIQUE | 2013年 / 69卷 / 02期
关键词：
EML4-ALK; Lung cancer; Crizotinib; Targeted therapy; Never smoker; Adenocarcinoma; EML4-ALK FUSION GENE; KINASE INHIBITOR; RESISTANCE; REARRANGEMENT; MUTATIONS; EFFICACY; MET; NPM;
D O I：
10.1016/j.pneumo.2012.11.010
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
Crizotinib is a small orally-administered ALK inhibitor for patients with non-small cell lung cancer with EML4-ALK rearrangement (echinoderm microtubule-associated protein-like 4 and anaplastic lymphoma kinase). This fusion gene is detected with a break apart fluorescence in situ hybridization (FISH) assay. Phase I to III trials have shown an interesting disease control rate and acceptable tolerability. Crizotinib is available in France under temporary use authorization. New potentially effective therapeutics in ALK-positive NSCLC are being developed. (C) 2013 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码：111 / 116
页数：6
相关论文
共 50 条
  • [21] Treatment of ALK-Positive Non-Small Cell Lung Cancer
    Bang, Yung-Jue
    ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2012, 136 (10) : 1201 - 1204
  • [22] Post-crizotinib management of effective ceritinib therapy in a patient with ALK-positive non-small cell lung cancer
    Won, Brian
    Mambetsariev, Isa
    Salgia, Ravi
    BMC CANCER, 2016, 16
  • [23] Post-crizotinib management of effective ceritinib therapy in a patient with ALK-positive non-small cell lung cancer
    Brian Won
    Isa Mambetsariev
    Ravi Salgia
    BMC Cancer, 16
  • [24] Circulating microRNAs as novel biomarkers of ALK-positive non-small cell lung cancer and predictors of response to crizotinib therapy
    Li, Liang-Liang
    Qu, Li-Li
    Fu, Han-Jiang
    Zheng, Xiao-Fei
    Tang, Chuan-Hao
    Li, Xiao-Yan
    Chen, Jian
    Wang, Wei-Xia
    Yang, Shao-Xing
    Wang, Lin
    Zhao, Guan-Hua
    Lv, Pan-Pan
    Zhang, Min
    Lei, Yang-Yang
    Qin, Hai-Feng
    Wang, Hong
    Gao, Hong-Jun
    Liu, Xiao-Qing
    ONCOTARGET, 2017, 8 (28) : 45399 - 45414
  • [25] Treating ALK-positive non-small cell lung cancer
    Ziogas, Dimitrios C.
    Tsiara, Anna
    Tsironis, Georgios
    Lykka, Maria
    Liontos, Michalis
    Bamias, Aristotelis
    Dimopoulos, Meletios-Athanasios
    ANNALS OF TRANSLATIONAL MEDICINE, 2018, 6 (08)
  • [26] Regarding the prognostic factors in patients with ALK-positive non-small cell lung cancer treated with crizotinib
    Hu, Limei
    Xie, Youjun
    Zhao, Hongying
    PULMONOLOGY, 2024, 30 (04): : 406 - 407
  • [27] Better Clinical Outcomes and Resistance Mechanisms of Crizotinib in ALK-Positive Non-Small Cell Lung Cancer
    Zhang, Y.
    Liang, Z.
    Li, Y.
    Yang, N.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S1003 - S1003
  • [28] Brigatinib for the treatment of ALK-positive advanced non-small cell lung cancer patients
    Passaro, A.
    Prelaj, A.
    Pochesci, A.
    Spitaleri, G.
    Rossi, G.
    Del Signore, E.
    Catania, C.
    de Marinis, F.
    DRUGS OF TODAY, 2017, 53 (08) : 435 - 446
  • [29] Initial phase II results with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC): PROFILE 1005
    Crino, L.
    Kim, D.
    Riely, G. J.
    Janne, P. A.
    Blackhall, F. H.
    Camidge, D. R.
    Hirsh, V.
    Mok, T.
    Solomon, B. J.
    Park, K.
    Gadgeel, S. M.
    Martins, R.
    Han, J.
    De Pas, T. M.
    Bottomley, A.
    Polli, A.
    Petersen, J.
    Tassell, V. R.
    Shaw, A. T.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [30] Complete remission for 4 years with crizotinib in advanced ALK-positive non-small cell lung cancer after thoracostomy for empyema
    Van Damme, Eufra
    Kiselinova, Maja
    Van Schoote, Elke
    TUMORI JOURNAL, 2019, 105 (06): : NP35 - NP37
12345